Beerse, Belgium

Sabine Karine Katrien Inghelbrecht

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2016-2023

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Inventor Spotlight: Sabine Karine Katrien Inghelbrecht

Introduction

Sabine Karine Katrien Inghelbrecht is a notable inventor based in Beerse, Belgium. With a remarkable portfolio that includes five patents, her contributions to the pharmaceutical field showcase innovative approaches to drug formulation and stability.

Latest Patents

Among her latest inventions is a patent for freeze-dried drug nanosuspensions. This invention pertains to a lyophilized drug nanosuspension composition, which demonstrates acceptable stability of the particle size distribution during both normal and long-term storage. Another significant patent is an aqueous pharmaceutical formulation of tapentadol for oral administration. This composition contains tapentadol or its physiologically acceptable salt, designed for oral delivery, and boasts excellent storage stability without the need for excessive preservatives.

Career Highlights

Throughout her career, Inghelbrecht has worked with esteemed companies, including Janssen Pharmaceutica and Grünenthal GmbH. Her experience in these leading pharmaceutical companies has played a crucial role in developing her patented inventions.

Collaborations

Sabine Karine Katrien Inghelbrecht has collaborated with a number of talented professionals, including Jakob Andreas Beirowski and Henning Gieseler. These partnerships have contributed to her innovative work and the successful development of her patents.

Conclusion

Sabine Karine Katrien Inghelbrecht stands out as an influential inventor in the pharmaceutical industry. Her groundbreaking patents illustrate her commitment to enhancing drug formulation and stability. As she continues her work, her contributions are expected to further impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…